Vyepti® (eptinezumab-jjmr)

Vyepti (eptinezumab‑jjmr) is covered for migraine prevention in adults ≥18 with ≥4 migraine days/month (recommended 100 mg IV every 3 months, approval up to 12 months); patients <18 and concurrent use of other CGRP inhibitors for migraine are excluded. Key requirements: documented failure or intolerance of ≥2 standard prophylactic therapies from different classes (waived if prior CGRP inhibitor or onabotulinumtoxinA use), documentation of baseline migraine frequency and prior therapy outcomes, and documented significant clinical benefit for continuation.

"Vyepti is indicated for the preventive treatment of migraine in adults."

Sign up to see full coverage criteria, indications, and limitations.